Segment, Geographic and Other Revenue Information - Revenues by Product (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue from External Customer [Line Items]
Revenues:	[1]	$ 58,496	$ 100,330	$ 81,288
Revenues—Alliance revenues	[2]	7,582	8,537	7,652
Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		57,186	98,988	79,557
Business Innovation Segment [Member]
Revenue from External Customer [Line Items]
Revenues:	[3]	1,310	1,342	1,731
Pfizer CentreOne [Member] | Business Innovation Segment [Member]
Revenue from External Customer [Line Items]
Revenues:	[4]	1,265	1,335	1,731
Pfizer Ignite [Member] | Business Innovation Segment [Member]
Revenue from External Customer [Line Items]
Revenues:		44	7	0
Total Alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues—Alliance revenues		7,582	8,537	7,652	[5]
Primary Care [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		30,589	73,023	52,029
Primary Care [Member] | Comirnaty Direct Sales and Alliance Revenues [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[6]	11,220	37,806	36,781
Primary Care [Member] | Eliquis Alliance Revenues and Direct Sales [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		6,747	6,480	5,970
Primary Care [Member] | Prevnar Family [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		6,440	6,337	5,272
Primary Care [Member] | Paxlovid [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[7]	1,279	18,933	76
Primary Care [Member] | Nurtec ODT/Vydura [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		928	213	0
Primary Care [Member] | Abrysvo [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		890	0	0
Primary Care [Member] | Premarin Family [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		397	455	563
Primary Care [Member] | BMP2 [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		338	277	266
Primary Care [Member] | FSME-IMMUN/TicoVac [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		268	200	185
Primary Care [Member] | Nimenrix [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		179	268	193
Primary Care [Member] | Trumenba [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		126	123	118
Primary Care [Member] | All other Primary Care [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		1,777	1,932	2,604
Specialty Care [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		14,970	13,833	15,194
Specialty Care [Member] | Vyndaqel Family [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		3,321	2,447	2,015
Specialty Care [Member] | Xeljanz [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		1,703	1,796	2,455
Specialty Care [Member] | Enbrel (Outside the U.S. and Canada) [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		830	1,003	1,185
Specialty Care [Member] | Sulperazon [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		757	786	683
Specialty Care [Member] | Ig Portfolio [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[8]	584	491	430
Specialty Care [Member] | Genotropin [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		539	360	389
Specialty Care [Member] | Zavicefta [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		511	412	413
Specialty Care [Member] | Inflectra [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		490	532	657
Specialty Care [Member] | BeneFIX [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		424	425	438
Specialty Care [Member] | Zithromax [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		406	331	278
Specialty Care [Member] | Medrol [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		339	328	432
Specialty Care [Member] | Oxbryta [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		328	73	0
Specialty Care [Member] | Somavert [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		267	268	277
Specialty Care [Member] | Fragmin [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		238	269	305
Specialty Care [Member] | ReFacto AF/Xyntha [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		230	239	304
Specialty Care [Member] | Cresemba [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		195	155	142
Specialty Care [Member] | Vfend [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		187	225	267
Specialty Care [Member] | Bicillin [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		158	146	120
Specialty Care [Member] | Cibinqo [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		128	27	0
Specialty Care [Member] | All other Anti-infectives [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		1,092	1,171	1,572
Specialty Care [Member] | All other Specialty Care [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		2,244	2,350	2,830
Oncology [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		11,627	12,132	12,333
Oncology [Member] | Ibrance [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		4,753	5,120	5,437
Oncology [Member] | Xtandi Alliance Revenues [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		1,191	1,198	1,185
Oncology [Member] | Inlyta [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		1,036	1,003	1,002
Oncology [Member] | Bosulif [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		645	575	540
Oncology [Member] | Lorbrena [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		539	343	266
Oncology [Member] | Zirabev [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		424	562	444
Oncology [Member] | Ruxience [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		390	458	491
Oncology [Member] | Xalkori [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		374	465	493
Oncology [Member] | Retacrit [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		340	394	444
Oncology [Member] | Aromasin [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		301	248	211
Oncology [Member] | Besponsa [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		236	219	192
Oncology [Member] | Braftovi [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[9]	213	194	187
Oncology [Member] | Bavencio Alliance Revenues [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[10]	190	271	178
Oncology [Member] | Sutent [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		180	347	673
Oncology [Member] | Mektovi [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		174	176	155
Oncology [Member] | Trazimera [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		91	203	197
Oncology [Member] | Padcev [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[11]	52	0	0
Oncology [Member] | Adcetris [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[11]	46	0	0
Oncology [Member] | Tukysa [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[11]	17	0	0
Oncology [Member] | Tivdak [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[11]	4	0	0
Oncology [Member] | All other Oncology [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		$ 433	$ 357	$ 238

[1] Earnings = Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s revenues and earnings in 2023 reflect a non-cash revenue reversal of $3.5 billion (see Note 17C). Biopharma’s earnings also include dividend income from our investment in ViiV of $265 million in 2023, $314 million in 2022 and $166 million in 2021.

[2] See Note 1G.

[3] See Note 17A above for information about Business Innovation. Prior-period financial information has been revised to reflect the current period presentation.

[4] PC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($33 million for 2023, $188 million for 2022, and $320 million for 2021), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships.

[5] Substantially all relates to amounts earned from our partners under co-promotion agreements. The decrease in 2023 was primarily driven by a decline in Alliance revenues from Comirnaty, partially offset by an increase in Alliance revenues from Eliquis. The increase in 2022 was primarily driven by increases in Alliance revenues from Eliquis, Comirnaty and Bavencio.

[6] Excludes revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the PC1 contract development and manufacturing organization. See footnote (h) below.

[7] Includes a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, of which a portion was associated with sales recorded in 2022, related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory.

[8] Immunoglobulin (Ig) portfolio includes the revenues from Panzyga, Octagam and Cutaquig.

[9] Erbitux is a registered trademark of ImClone LLC.

[10] In March 2023, it was announced that our alliance with Merck KGaA to co-develop and co-commercialize Bavencio (avelumab) would terminate. Effective June 30, 2023, Merck KGaA took full control of the global commercialization of Bavencio. Beginning in the third quarter of 2023, the related profit share was replaced by a 15% royalty to Pfizer on net sales of Bavencio, which was recorded in Other (income)/deductions––net. We and Merck KGaA continue to operationalize our respective ongoing clinical trials for Bavencio; and Merck KGaA controls all future R&D activities. Bavencio is a registered trademark of Merck KGaA.

[11] Represents revenues from legacy Seagen products subsequent to the acquisition on December 14, 2023. See Note 2A.